Partnering opportunity

French pre-clinical biotech company offers its expertise in drug discovery and repurposing to identify personnalized medicine for patients with rare monogenetic diseases

Summary

A French pre-clinical biotech company offers its expertise in drug discovery and repurposing to identify personalised medicine for patients with rare monogenetic diseases, under the scope of a technical or a research cooperation agreement with patient associations, academic organisations and private companies.

Partner sought

The French company is looking to collaborate with patient organisations, academic stakeholders or private companies that would like to benefit from its expertise, know-how, and technology. It is offering to cooperate under a technology or a research cooperation agreement, providing its services to help patients with rare skin diseases and no currently idetified treatment.

Description

The French company is a pre-clinical biotech company with a strong expertise in the fild of monogenetic disorders designing and developing miniaturised and automated in vitro cellular and phenotypic assays based on the use of patient cells. It is developing its first drug-candidate in the field of inborn skin diseases. The company is already working closely with several patient organisations in the following areas of expertise: screening molecules, drug repurposing, inherited metabolic disorders, genodermatoses and inborn neurodevelopmental disorders. It has research laboratories with facilities for cell culture, cellular biology, molecular biology, biochemistry and chemistry. It is based into a very fruitful environment with excellent healthcare science. The process implemented by the company is the following: - it collects biopsies from patients with a well-established monogenetic disorder in order to isolate fibroblasts and keratinocytes that are amplified and biobanked through its own database. - assays are then developed using these primary or immortalized attaching cells in a standard format 384-well plates. - the company uses imaging, spectrometry and mass spectrometry to follow the most clinically-relevant phenotypes of the diseased cells for screening molecules. The technology can be easily settled for using other types of attaching cells. The development of a miniaturized 2D reconstituted skin suitable for high throughput screening is on-going. The company has assembled its own and proprietary collection of molecules approved for human use that is suitable for drug repurposing. The collection contains Active Pharmaceutical Ingredients (APIs), excipients, Generally Recognized As Safe (GRAS), food supplements and phase one metabolites of APIs. It is looking to enhance collaborations with patient associations, as well as academic organisations and private companies on drug discovery projects for molecule screening on patient primary cells and drug repurposing, offering research or technical cooperation agreements.

Advantages and innovations

The company has developed technology and know-how that provides the most relevant screening assays for monogenetic disorders. The company's main innovations can be described as follow: 1/ Fibroblasts and keratinocytes isolation and bio-banking from skin biopsies coming from patient with a diagnosed monogenetic disorder. 2/ Miniaturized and automated cellular screening assays. 3/ Microscopy facilities for HT screening on living cells. 4/ Mass spectrometry coupled with liquid chromatography adapted for HT screening based on metabolomic and fluxomic experiments. 5/ High throughput screening know-how and facilities. 6/ Original and proprietary collection of molecules approved for human use that allows drug candidates identification for repurposing and new therapeutic targets and pathways. 7/ Privileged access to 100k original molecules library 8/ Privileged access to Absorption, Distribution, Metabolism, and Excretion (ADME) in vitro %26 in vivo facilities. 9/ Strong network of medical doctors in the field of inborn error of metabolism and genodermatoses.

Development stage

Already on the market

Intellectual Property Rights (IPR)

Secret Know-how,Patents granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company